Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975096 | 0.85 | BRD4 (0.56) | BRD4EPAS1VEGFASLC22A12CYP11B1 | |
| SCHEMBL3510232 | 0.82 | PGR (0.52) | BRD4EPAS1VEGFA | |
| SCHEMBL15067760 | 0.81 | SMN1; SMN2 (0.66) | BRD4SMN1; SMN2HTT | |
| SCHEMBL890912 | 0.77 | EPAS1 (0.46) | EPAS1VEGFASLC22A12AR | |
| SCHEMBL890666 | 0.76 | GAA (0.58) | EPAS1VEGFAAR | |
| SCHEMBL890626 | 0.75 | USP2 (0.66) | EPAS1HTTVEGFACYP11B1CYP11B2 | |
| SCHEMBL10833690 | 0.74 | HRH3 (0.50) | BRD4EPAS1HTTSLC22A12CYP11B1 | |
| SCHEMBL24749740 | 0.74 | AR (0.55) | EPAS1SMN1; SMN2VEGFAAR | |
| SCHEMBL31694899 | 0.74 | AR (0.55) | EPAS1SMN1; SMN2VEGFAAR | |
| SCHEMBL891091 | 0.74 | L3MBTL1 (0.65) | EPAS1VEGFAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9108922-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8518977-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8063036-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-6844367-B1 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-6835739-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040097561-A1 | For therapy of thrombosis | MILLENNIUM PHARMACEUTICALS, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20030162690-A1 | Bood anticoagulant | COR THERAPEUTICS, INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1259485-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1216228-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6376515-B2 | DERIVATIVES OF A 2-((4-AMIDINYLPHENYL)-CARBONYLAMINO-1,2-PHENYLENE)-CARBONYLAMINO-) PYRIDINE; POTENT AND HIGHLY SELECTIVE ANTICOAGULANTS; BIOAVAILABILITY AND/OR SOLUBILITY; PREVENTION AND TREATMENT OF THROMBOSIS AND COAGULATION | COR THERAPEUTICS, INC. | 2002-04-23 | — | — | US | disclosed |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001064643-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001019788-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | BRD4 400/4885EPAS1 898/4885SMN1; SMN2 1977/4885 |
| US-20040097561-A1 | For therapy of thrombosis | F2, F12, TFPI | BRD4 1066/4885EPAS1 645/4885SMN1; SMN2 2263/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | BRD4 400/4885EPAS1 898/4885SMN1; SMN2 1977/4885 |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | BRD4 400/4885EPAS1 898/4885SMN1; SMN2 1977/4885 |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | BRD4 400/4885EPAS1 898/4885SMN1; SMN2 1977/4885 |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | BRD4 400/4885EPAS1 898/4885SMN1; SMN2 1977/4885 |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | F2, F12, PLAT | BRD4 916/4885EPAS1 611/4885SMN1; SMN2 1172/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | BRD4 400/4885EPAS1 898/4885SMN1; SMN2 1977/4885 |
| US-20030162690-A1 | Bood anticoagulant | F2, SERPINC1, HABP2 | BRD4 331/4885EPAS1 1710/4885SMN1; SMN2 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.